key: cord-0935530-j63jgvbc
authors: Hillman, Richard; Cuming, Tamzin; Jay, Naomi; Goldstone, Stephen; Berry‐Lawhorn, Michael; Barroso, Luis; Nathan, Mayura; Palefsky, Joel
title: Do we really need guidelines for HRA during COVID‐19 pandemic? ‐ Response
date: 2020-06-21
journal: Colorectal Dis
DOI: 10.1111/codi.15203
sha: 07c7aabab952bb24955fa530a707c3fe7e9b2a6d
doc_id: 935530
cord_uid: j63jgvbc

Mistrangelo et al raise a number of issues in connection with the International Anal Neoplasia Society guidelines for the practice of High Resolution Anoscopy (HRA) in the era of COVID‐19. The authors suggest that the guidelines advocate “mandatory” HRA for “screening”. On the contrary, the guidelines clearly define risk prioritisation, in terms of both potential COVID‐19 exposure and the dangers associated with delayed diagnosis of anal cancers. Centres without access to high quality HRA services may have to rely on digital anal rectal examination to eventually diagnose large anal cancers. HRA has the ability to accurately identify early anal cancers and worrisome pre‐cancerous lesions, and thus to facilitate early intervention. It therefore has the capacity to substantially improve survival and quality of life of patients. This remains true in the era of COVID‐19, and will be of increasing importance as the epidemic continues and services remain disrupted.

iv) Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

i) Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND ii) Drafting the work or revising it critically for important intellectual content; AND

This article is protected by copyright. All rights reserved iii) Final approval of the version to be published; AND iv) Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

i) Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND ii) Drafting the work or revising it critically for important intellectual content; AND iii) Final approval of the version to be published; AND iv) Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

i) Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND ii) Drafting the work or revising it critically for important intellectual content; AND iii) Final approval of the version to be published; AND iv) Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

i) Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND ii) Drafting the work or revising it critically for important intellectual content; AND iii) Final approval of the version to be published; AND iv) Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

This article is protected by copyright. All rights reserved 

None of the authors have any conflicts of interest to declare

This article is protected by copyright. All rights reserved The authors suggest that the guidelines advocate "mandatory" HRA for "screening". On the contrary, the guidelines clearly define risk prioritisation, in terms of both potential COVID-19 exposure and the dangers associated with delayed diagnosis of anal cancers.

Centres without access to high quality HRA services may have to rely on digital anal rectal examination to eventually diagnose large anal cancers. HRA has the ability to accurately identify early anal cancers and worrisome pre-cancerous lesions, and thus to facilitate early intervention. It therefore has the capacity to substantially improve survival and quality of life of patients. This remains true in the era of COVID-19, and will be of increasing importance as the epidemic continues and services remain disrupted.

This article is protected by copyright. All rights reserved

This manuscript seeks to correct a potentially misleading article recently published in Colorectal Disease. In an era where infection control issues are paramount, riskprioritisation is critical. Quality HRA services, where available, permit the safe, early diagnosis and treatment of patients with anal cancer.

We appreciate Mistrangelo et al bringing to our attention the use of high resolution anoscopy (HRA) in the era of the COVID-19 pandemic. However, the authors focus on the role of HRA in screening, and make a suggestion that HRA is "mandatory"(1) . We believe that their perspectives are potentially misleading, as neither of these points are mentioned in the original guidelines(2).

The International Anal Neoplasia Society (IANS) guidelines were first published on 8 April 2020, in response to multiple enquiries from our members, and others, at a time of great confusion and anxiety amongst practitioners from many different jurisdictions around the world. They drew on the latest available evidence at the time, and received input from a wide range of experts in the field.

Many organisations have issued guidelines regarding the management of cancer in the era of COVID-19(3). In England, for example, a new diagnosis of anal cancer would clearly be allocated a "Priority level 1", as curative therapy has a high (>50%) chance of successful treatment(4). Newly diagnosed anal cancers have better outcomes when diagnosed early(5), with increasing evidence that chemoradiotherapy may be avoided in smaller cancers such as superficially invasive squamous cell cancers (6) .

Whilst digital anal rectal examination (DARE) is an important first step in the evaluation of all symptomatic patients, this unfortunately has a very limited evidence base and may have significant false negative rates (7) . In centres with highly trained practitioners, subject to robust quality assurance measures (8) , HRA offers the unique ability, like colonoscopy, to detect cancers at an order of magnitude greater than those by palpation at DARE (6) .

This article is protected by copyright. All rights reserved IANS is focussed on the prevention and early diagnosis of anal cancers. Our patients are often drawn from the very vulnerable populations most at risk for COVID-19, such as the immunocompromised. It is becoming increasingly clear that many months or years will pass before the risk of COVID-19 is reduced to a level where these guidelines are no longer necessary. Progression to anal cancer is likely to occur in some patients during this period.

The IANS' guidelines, like others in similar fields, suggest a reasonable approach to care in these difficult times.

Do we really need guidelines for HRA during COVID-19 pandemic? Colorectal Dis. 2020. 2. International Anal Neoplasia Society. IANS Guidelines for the practice of HRA in the era of COVID-19 2020

Cancer guidelines during the COVID-19 pandemic. The Lancet Oncology

Clinical guide for the management of noncoronavirus patients requiring acute treatment: Cancer 2020

Chemoradiotherapy for anal cancer: are we as good as we think?

Outcome of excision of early invasive squamous carcinomas of the anal canal and perianus

International Anal Neoplasia Society Guidelines for the Practice of Digital Anal Rectal Examination

IANS International Guidelines for Practice Standards in the Detection of Anal Cancer Precursors

Accepted Article